Plus, check out our handy semaglutide weight loss dosage chart for an easy-to-follow overview of what to expect. Semaglutide is the active ingredient in three medications approved by the U.S. Food ...

Two Omaha women lost more than 300 lbs. combined with injections of a GLP-1 drug, which are used increasingly for weight loss ...

A new study suggests that medications that have transformed the treatment of obesity may also help people drink less alcohol.

Compounded weight-loss medications, such as those promoted in the Hims & Hers commercial, aren’t approved by the Food and Drug Administration.

The bar chart below compares the rate of NAION ... Prof Sattar says people who are not obese but access semaglutide privately to lose weight may suffer this side effect, as he is not familiar ...

Novo Nordisk thrives despite competition and explore its breakthrough amycretin study. Read here to know why we rate NVO ...

Superior dose-dependent weight loss was also observed upon treatment ... and the S&P 500 during the same time frame, as seen in the chart below. NVO is currently trading below both its 50 and ...

The obesity market size is projected to witness growth from 2024 to 2034 due to the rising prevalence of obesity. This expansion is expected to be fu ...

Novo Nordisk's 2024 earnings exceeded estimates, with strong performance in diabetes, obesity, and rare disease segments.

Novo Nordisk NVO is scheduled to report fourth-quarter 2024 results on Feb. 5, 2025, before the opening bell. The Zacks Consensus Estimate for quarterly revenues in the to-be-reported quarter is ...